QuidelOrtho (QDEL) Stock Spikes 37% on Reported $1.5 Billion Testing-Unit Sale Talks

QuidelOrtho Corporation (NASDAQ: QDEL) was among the standout gainers of the session on Monday, June 29, 2026, surging 37.3% to $18.92 in one of the day's most dramatic single-stock moves. The catalyst was not earnings but a fast-developing M&A story: multiple reports, initially via the Financial Times and echoed by Bloomberg and Seeking Alpha, indicated the company is weighing a sale of its point-of-care testing unit for about $1.5 billion. The targeted business is best known for its rapid COVID-19 antigen tests. According to reports, the sale process has reached an advanced stage, with private equity firms including Advent International, SK Capital Partners and Archimed said to be evaluating bids. There is no guarantee a deal closes, but the market reacted decisively to the prospect. The strategic logic centers on the balance sheet. QuidelOrtho carries roughly $3.8 billion in debt, much of it accumulated through its 2022 acquisition of Ortho Clinical Diagnostics. Proceeds from divesting the point-of-care unit would give management a direct lever to pay down leverage and refocus the portfolio on its core clinical diagnostics and laboratory franchise. For a stock that had been deeply out of favor, that narrative was enough to spark heavy buying. A Jefferies analyst characterized a potential sale as 'a net positive for the company,' while cautioning that the firm awaited additional details before drawing firmer conclusions. That measured tone underscores that the rally is built on a reported, not yet confirmed, transaction. Context frames just how sharp Monday's bounce was. Even after the spike, QDEL remained down roughly 35% year-to-date and sat well below its 52-week high of $35.38 set in January 2026. The stock is notably volatile, regularly posting moves exceeding 5%. June also brought leadership change, with QuidelOrtho appointing Micah Young as CFO effective July 6, succeeding the retiring Joseph Busky. For investors, the move recasts QuidelOrtho as a deleveraging and portfolio-simplification story. The upside hinges on execution: confirmation of a buyer, the final price, and how aggressively proceeds are applied to debt. Until a definitive agreement is announced, the gains carry deal-risk, and any sign the talks stall could reverse Monday's enthusiasm just as quickly as it arrived. Sources: FinancialContent/StockStory, Bloomberg, Seeking Alpha, TheStreet.